$ News

SERB Pharmaceuticals Completes Acquisition of Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?

Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates

YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?

Y-mAbs Therapeutics: The Next Deal Showcases The Value And Challenges Of Biotech M&A

SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

Y-mAbs Therapeutics First Quarter 2025 Earnings: Beats Expectations

Y-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges

Q1 2025 Y-mAbs Therapeutics Inc Earnings Call